TherapeuticsMD (TXMD) AI Stock Analysis

• Market Cap: $23.84M
• Dividend Yield: N/A
• Average Volume (3M): 310.58K
• Price to Earnings (P/E): 78.9
• Beta (1Y): 1.37
• Revenue Growth: 75.19%
• EPS Growth: N/A
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.01
• Shares Outstanding: 11,574,362
• 10 Day Avg. Volume: 897,126
• 30 Day Avg. Volume: 310,579
• PEG Ratio: 0.07
• Price to Book (P/B): 0.36
• Price to Sales (P/S): 5.63
• P/FCF Ratio: 8.48
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 4.99
• Enterprise Value/Gross Profit: 5.17
• Enterprise Value/Ebitda: -14.33
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $1.50 ▼(-10.71% Downside)

The score is driven primarily by improving (but still mixed) financial performance—positive cash flow and narrowing losses offset by weak operating margins. Technicals are moderately supportive with price above major moving averages, while valuation is a key constraint due to the elevated P/E and lack of dividend support. Corporate events add a small positive tilt but are not decisive.

Positive Factors

Revenue Growth

The increase in license revenue indicates a successful transition to a royalty-based model, enhancing long-term revenue stability.

Cost Management

Effective cost management through reduced operating expenses improves profitability prospects and financial sustainability.

Strategic Initiatives

Pursuing strategic alternatives can unlock new growth opportunities and enhance competitive positioning in the industry.

Negative Factors

Declining Revenues

A drop to zero revenue reflects severe operational challenges, threatening the company's ability to sustain its business model.

Profitability Issues

Ongoing profitability issues highlight operational inefficiencies and raise concerns about long-term financial viability.

Balance Sheet Health

High leverage indicates financial strain, limiting flexibility and increasing risk in adverse market conditions.

TherapeuticsMD Business Overview & Revenue Model

Company Description

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

How the Company Makes Money

TherapeuticsMD generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include the sales of its FDA-approved hormone therapy products and prenatal vitamins. TherapeuticsMD also engages in partnerships with healthcare providers and pharmacies to distribute its products, enhancing its market reach and accessibility. Additionally, the company may engage in licensing agreements and collaborations with other pharmaceutical companies to leverage its research and development capabilities, thus contributing to its earnings.

TherapeuticsMD Financial Statement Overview

Summary

TherapeuticsMD's financial statements reveal a company facing significant financial difficulties. The income statement reflects ongoing challenges with revenue generation and profitability. The balance sheet shows improved equity but remains strained by liabilities. Cash flow statements indicate some recovery in free cash flow, but historical volatility persists. The company must address these challenges to improve its financial health and stability.

Income Statement

TherapeuticsMD has faced declining revenues, with Total Revenue dropping to zero in the latest annual report. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. Despite previous periods of profitability, recent financials show significant losses, resulting in a low score.

Balance Sheet

The company's balance sheet shows high leverage with a debt-to-equity ratio of approximately 0.20 in the latest period. While stockholders' equity has improved from negative in earlier years, the overall financial health remains weak due to high liabilities relative to assets. This balance of negative and positive factors results in a moderate score.

Cash Flow

There has been a significant improvement in free cash flow, transitioning from negative to positive in the most recent year. However, the company's operating cash flow has fluctuated significantly over the years. The improvements in free cash flow provide a slightly better outlook but overall cash flow stability remains a concern, leading to a moderate score.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.80M	1.76M	1.30M	69.96M	2.57M	64.87M
Gross Profit	2.70M	1.76M	1.30M	68.57M	1.17M	48.90M
EBITDA	-974.00K	-2.98M	-8.08M	11.86M	-70.84M	-153.41M
Net Income	302.00K	-2.18M	-10.28M	112.00M	-172.41M	-183.52M
Balance Sheet
Total Assets	38.67M	38.82M	43.31M	90.46M	169.47M	181.61M
Cash, Cash Equivalents and Short-Term Investments	7.12M	5.06M	4.33M	38.07M	64.91M	80.49M
Total Debt	6.48M	7.17M	8.01M	8.76M	197.69M	248.63M
Total Liabilities	11.23M	11.45M	14.02M	55.31M	263.09M	305.61M
Stockholders Equity	27.44M	27.37M	29.29M	35.14M	-93.62M	-124.00M
Cash Flow
Free Cash Flow	2.07M	732.00K	0.00	-4.43M	-147.84M	-161.07M
Operating Cash Flow	2.07M	732.00K	-48.14M	-4.08M	-147.81M	-159.47M
Investing Cash Flow	0.00	0.00	0.00	223.48M	-2.22M	-1.60M
Financing Cash Flow	0.00	0.00	3.15M	-235.21M	134.67M	80.72M

TherapeuticsMD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Positive. The current price of 1.68 is below the 20-day moving average (MA) of 1.76, above the 50-day MA of 1.61, and above the 200-day MA of 1.27, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 68.25 is Neutral, neither overbought nor oversold. The STOCH value of 81.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TXMD.

TherapeuticsMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TXMD	54 Neutral	$23.84M	78.93	0.27%	―	75.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	49 Neutral	$27.10M	-0.87	-50.23%	―	-15.61%	-68.96%
RDHL	47 Neutral	$6.82M	―	―	―	―	―
PRPH	41 Neutral	$1.23M	-0.01	―	―	―	―

TherapeuticsMD Corporate Events

TherapeuticsMD Approves Key Proposals at Annual Meeting

On December 15, 2025, TherapeuticsMD, Inc. held its 2025 Annual Meeting where stockholders voted on several key proposals. These included the election of four directors, approval of executive compensation, determination of voting frequency for executive compensation, ratification of an independent auditor, and an amendment to increase authorized shares. All proposals were approved, indicating strong shareholder support and potentially positioning the company for future growth and strategic initiatives.

TherapeuticsMD Reports Q3 2025 Financial Results

On November 12, 2025, TherapeuticsMD announced its financial results for the third quarter of 2025, reporting a net income of $50 thousand, a significant improvement from a net loss of $567 thousand in the same period of 2024. The company also reported an increase in license revenue to $784 thousand, primarily from the Mayne License Agreement, and a slight decrease in operating expenses. As of September 30, 2025, the company’s cash and cash equivalents totaled $7.1 million. TherapeuticsMD is evaluating strategic alternatives, including potential acquisitions or mergers, but has not set a timetable for these explorations.